Literature DB >> 21397263

Surgical conversion after thoracic endovascular aortic repair.

Ludovic Canaud1, Pierre Alric, Thomas Gandet, Bernard Albat, Charles Marty-Ané, Jean-Philippe Berthet.   

Abstract

OBJECTIVE: Improved early and late outcomes of thoracic endovascular aortic repair compared with open repair have changed the therapeutic paradigm of thoracic aortic lesions. However, rare but serious complications due to device failure or adverse events may occur, requiring conversion to open repair.
METHODS: In our experience, 186 patients underwent thoracic endovascular aortic repair. Seven of these patients (3.7%) required open repair because of 3 retrograde type A dissections, 1 thoracic stent-graft collapse, 1 aneurysm enlargement without endoleak, 1 aortoesophageal fistula, and 1 stent-graft infection. All patients but 1 underwent surgical repair using cardiopulmonary bypass. Four stent-grafts were totally removed, and 3 endografts were left in situ. Three patients underwent supracoronary ascending aorta replacement via a sternotomy. Three patients underwent a descending aortic replacement via a left thoracotomy. One patient was treated by ligation of the aortic arch, ascending to supraceliac abdominal aorta bypass, and stent-graft explantation.
RESULTS: Thirty-day mortality was 28%. Four patients had an uneventful postoperative course. One patient was treated for postoperative sternitis. Two patients with stent-graft infections died of multiorgan failure in the early postoperative course. No stroke, paraplegia, or renal failure occurred. With a mean follow-up of 21.4 months (range, 2-60 months), 5 patients had no adverse events.
CONCLUSIONS: Complications due to device failure or adverse events may occur after thoracic endovascular aortic repair, requiring conversion to open repair. Our experience suggests that in some clinical or anatomic situations, caution should be recommended when offering endovascular procedures to patients with thoracic aortic diseases. Open conversion can be performed with encouraging results by a team experienced in the management of thoracic aortic diseases. With the increasing use of thoracic endovascular aortic repair, more patients will present with indications of surgical conversion.
Copyright © 2011 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21397263     DOI: 10.1016/j.jtcvs.2011.01.060

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  6 in total

1.  When stent-grafts fail: extraction and open surgical repair of the thoracic aorta.

Authors:  Joseph S Coselli; Susan Y Green; Scott A LeMaire
Journal:  Tex Heart Inst J       Date:  2011

2.  Secondary aortoesophageal fistula after thoracic aortic aneurysm endovascular repair: literature review and new insights regarding the hypothesized mechanisms.

Authors:  Er-Ping Xi; Jian Zhu; Shui-Bo Zhu; Yu Zhang
Journal:  Int J Clin Exp Med       Date:  2014-10-15

3.  Endovascular repair as a bridge to surgical repair of an aortobronchial fistula complicating chronic residual aortic dissection.

Authors:  Jesus M Matos; Kim I de la Cruz; Maral Ouzounian; Ourania Preventza; Scott A LeMaire; Joseph S Coselli
Journal:  Tex Heart Inst J       Date:  2014-04-01

4.  Aneurysm growth after late conversion of thoracic endovascular aortic repair.

Authors:  Hirofumi Kasahara; Ichiro Hayashi; Norimasa Haijima
Journal:  SAGE Open Med Case Rep       Date:  2015-01-08

5.  Old Solutions for New Troubles in Complications after Thoracic Endovascular Aortic Repair.

Authors:  German Alberto Fortunato; Guillermo Stöger; Ricardo Gustavo Marenchino; Vadim Kotowicz
Journal:  Thorac Cardiovasc Surg Rep       Date:  2017-08-25

Review 6.  Retrograde Type A Aortic Dissection After Thoracic Endovascular Aortic Repair: A Systematic Review and Meta-Analysis.

Authors:  Yanqing Chen; Simeng Zhang; Lei Liu; Qingsheng Lu; Tianyi Zhang; Zaiping Jing
Journal:  J Am Heart Assoc       Date:  2017-09-22       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.